After helping build one of biotech's biggest success stories, Noubar Afeyan is continuing to back high-risk science through ideas generated by his own research teams. The strategy reflects a willingness to commit millions of dollars annually to concepts that many investors might consider too speculative at an early stage.
Highlights
- Moderna Inc., co-founded by Noubar Afeyan in 2010, has reached a valuation near $80 billion, driven by its pioneering mRNA platform.
- Moderna and Merck & Co. are expanding into the cancer market with a personalized skin cancer vaccine, fueling Moderna shares to rise over 500% this year.
- Investor optimism centers on biotech companies like Moderna that leverage internal scientific innovation to create commercial drug franchises beyond single products.
Track record built on improbable science
As reported by Bloomberg, biochemical engineer Noubar Afeyan has long focused on ideas that appear unlikely to succeed at first. In 2010, he co-founded Moderna Inc. to use the body's own cells as small platforms for producing drugs, a concept that initially drew skepticism.That wager develops into one of the most prominent biotech startup stories in recent decades. Moderna is now valued at nearly $80 billion and remains best known for its Covid-19 vaccine.
Cancer expansion sharpens market focus
Moderna is also extending its messenger RNA business into the cancer market with partner Merck & Co. The companies' personalized skin cancer vaccine effort is helping fuel investor optimism, with Moderna shares up more than 500% so far this year.Afeyan's continued focus on internally developed, far-reaching scientific ideas underscores how parts of the biotech sector are still rewarding platforms with potential beyond a single product. The approach also highlights ongoing investor interest in companies that can turn experimental science into commercial drug franchises.
Our earlier article on AstraZeneca’s AI-driven drug discovery partnership with insitro explained how the companies aim to use a “Virtual Human” platform to identify targets for MASH and cardiomyopathies and advance them to development-candidate stage. We noted that the deal structure pairs AI-enabled early research with AstraZeneca’s funding and clinical-trial capabilities, reflecting the wider industry push to speed up R&D and improve target selection in tough disease areas.
Latest Pharmaceutical Industry News
-
Afghanistan
-
Albania
-
Algeria
-
Angola
-
Argentina
-
Armenia
-
Australia
-
Austria
-
Azerbaijan
-
Bahamas
-
Bahrain
-
Bangladesh
-
Belarus
-
Belgium
-
Bolivia
-
Botswana
-
Brazil
-
Brunei
-
Bulgaria
-
Cambodia
-
Cameroon
-
Canada
-
Chile
-
China
-
Colombia
-
Congo
-
Costa Rica
-
Cote d'Ivoire
-
Croatia
-
Cuba
-
Cyprus
-
Czechia
-
DR Congo
-
Denmark
-
Dominican Republic
-
Ecuador
-
Egypt
-
El Salvador
-
Estonia
-
Eswatini
-
Ethiopia
-
Finland
-
France
-
Georgia
-
Germany
-
Ghana
-
Greece
-
Haiti
-
Hong Kong
-
Hungary
-
India
-
Indonesia
-
Iran, Islamic republic
-
Iraq
-
Ireland
-
Israel
-
Italy
-
Jamaica
-
Japan
-
Jordan
-
Kazakhstan
-
Kenya
-
Korea
-
Kuwait
-
Kyrgyzstan
-
Laos
-
Latvia
-
Lebanon
-
Lesotho
-
Libya
-
Lithuania
-
Luxembourg
-
Madagascar
-
Malaysia
-
Malta
-
Mauritius
-
Mexico
-
Moldova
-
Mongolia
-
Montenegro
-
Morocco
-
Mozambique
-
Myanmar
-
Namibia
-
Nepal
-
Netherlands
-
New Zealand
-
Nigeria
-
North Macedonia
-
Norway
-
Oman
-
Pakistan
-
Palestine
-
Panama
-
Papua New Guinea
-
Paraguay
-
Peru
-
Philippines
-
Poland
-
Portugal
-
Puerto Rico
-
Qatar
-
Reunion
-
Romania
-
Rwanda
-
Saudi Arabia
-
Serbia
-
Singapore
-
Slovakia
-
Slovenia
-
Somalia
-
South Africa
-
Spain
-
Sri Lanka
-
Sweden
-
Switzerland
-
Syria
-
Taiwan
-
Tajikistan
-
Tanzania
-
Thailand
-
Trinidad and Tobago
-
Tunisia
-
Turkey
-
UAE
-
Uganda
-
Ukraine
-
United Kingdom
-
United States
-
Uruguay
-
Uzbekistan
-
Venezuela
-
Vietnam
-
Yemen
-
Zambia
-
Zimbabwe
- Forex
- Crypto
